Zynerba's cannabis-based epilepsy gel fails study, shares plunge
Zynerba Pharmaceuticals Inc said on Monday its synthetic cannabis-based gel to treat epilepsy failed a mid-stage study, sending the U.S. drug developer's shares plunging 50 percent. In the study, two doses of Zynerba's gel — also its lead experimental drug — were tested in adults suffering from epilepsy with partial seizures, those that occur when epileptic activity takes part in a localized part of the brain. Data from studies evaluating the gel's use in osteoarthritis patients and in children with Fragile X Syndrome, a genetic condition, is expected later this year.
Royal Industry News
Top news stories about the automotive industry. And, news from around the world.